A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

November 20, 2023

Study Completion Date

October 21, 2024

Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG

Ofatumumab

Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)

Trial Locations (20)

12110

Ms Ctr Of Northeastern Ny, Latham

21093

International Neurorehab Institute, Lutherville

32312

AMO Corporation, Tallahassee

33024

Infinity Clinical Research LLC, Hollywood

33612

University Of South Florida, Tampa

35209

Alabama Neurology Associates PC, Birmingham

37922

Sibyl Wray MD Neurology PC, Knoxville

43082

Columbus Neuroscience, Westerville

75325

Parkland Health and Hospital Systems, Dallas

78681

Central TX Neuro Consultants P A, Round Rock

80045

UC Health Neuroscience Ctr, Aurora

85018

Ctr for Neurology and Spine, Phoenix

89106

Cleveland Clinic Foundation, Las Vegas

91767

Neuro Center, Pomona

98122

Swedish Neuroscience Institute, Seattle

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Cente, Boston

02035

Neurology Center of New England PC, Foxborough

02481

Dragonfly Research LLC, Wellesley

00968

Caribbean Center for Clinical Research, Inc, Guaynabo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY